NCT03127592
Phase III Efficacy and Tolerability Trial of the Fixed Dose Combination of Etodolac 400 mg and Cyclobenzaprine 10 mg Versus Isolated Active Substances in Pain Control After Impacted Third Molar Extraction
Phase: Phase 3
Role: Lead Sponsor
Start: Oct 5, 2020
Completion: Jul 26, 2022